Improving diagnosis and treatment for interstitial lung diseases
Integrating Molecular, Genomic, Morphology and Environmental Features to Improve Precision Diagnosis and Treatment in Interstitial Lung Diseases (PRECISION-ILD)
This study is trying to find better ways to diagnose and treat interstitial lung diseases by looking at genetic and lifestyle factors that affect how the disease progresses and responds to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Sex | All |
| Sponsor | Institut d'Investigació Biomèdica de Bellvitge Academic / other |
| Locations | 3 sites (Hospitalet de Llobregat, Barcelona and 2 other locations) |
| Trial ID | NCT05998512 on ClinicalTrials.gov |
What this trial studies
This observational study aims to enhance the precision of diagnosis and treatment for interstitial lung diseases (ILDs) by integrating molecular, genomic, morphological, and environmental data. It focuses on understanding the genetic and lifestyle factors that influence the progression and treatment response of fibrotic ILDs. By analyzing these diverse features, the study seeks to identify biomarkers that can predict patient outcomes and tailor therapies accordingly.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old who have been diagnosed with fibrotic ILD within the last 12 months.
Not a fit: Patients with severe, life-limiting chronic diseases or those unable to comply with the study protocol may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more accurate diagnoses and personalized treatment plans for patients with interstitial lung diseases.
How similar studies have performed: While there have been studies focusing on specific aspects of ILDs, this comprehensive approach integrating multiple factors is relatively novel and untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion criteria: * Age \> 18 years * Signed informed consent * Diagnosis of fibrotic ILD of any type in the 12 months prior to inclusion. * Radiologic fibrotic changes of at least 5% on chest CT scan * Ability to comply with the study protocol (in the opinion of the investigator) * Ability to understand the information given and to sign the informed consent form. Exclusion Criteria * Severe, advanced stage or life-limiting chronic diseases prior to the diagnosis of fibrotic ILD, or that represent a high risk of death in the short term (one year after inclusion), such as could be metastatic oncological metastatic diseases, advanced dementia, neurodegenerative diseases in a limiting phase. * Pregnancy or breastfeeding * Inability to complete required visits.
Where this trial is running
Hospitalet de Llobregat, Barcelona and 2 other locations
- Hospital Universitario de Bellvitge — Hospitalet de Llobregat, Barcelona, Spain (Recruiting)
- Hospital La Princesa — Madrid, Spain (Recruiting)
- Hospital Virgen del Rocío — Sevilla, Spain (Recruiting)
Study contacts
- Study coordinator: Maria Molina
- Email: ufip@bellvitgehospital.cat
- Phone: 932607500
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.